F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have patented 5-[2,7-diazaspiro[3.5]nonan-7-yl]-5-[4-phenoxyphenyl]hexahydropyrimidine-2,4,6-trione derivatives acting as matrix metalloproteinase-9, (MMP-9) inhibitors potentially useful for the treatment of dry eye.
Astrazeneca AB has reported the identification of 17β-hydroxysteroid dehydrogenase 13 (HSD17B13; 17β-HSD13) inhibitors reported to be useful for the treatment of nonalcoholic steatohepatitis (NASH; MASH), among others.
An Eli Lilly & Co. patent describes new relaxin receptor 1 (RXFP1; LGR7) agonists potentially useful for the treatment of diabetes, stroke, atherosclerosis and more.
Absent extraordinary circumstances, the Patent Trial and Appeal Board “should never cancel claims it has not determined to be unpatentable as a sanction” for misconduct during a board proceeding, according to the acting director of the U.S. Patent and Trademark Office (USPTO).
Vertex Pharmaceuticals Inc. has described polycystin-1 (PKD1) (mutant) correctors reported to be useful for the treatment of autosomal dominant polycystic kidney disease.
Astrazeneca AB has divulged 17β-hydroxysteroid dehydrogenase 13 (HSD17B13; 17β-HSD13) inhibitors reported to be useful for the treatment of alcoholic liver disease, liver fibrosis, cirrhosis, hepatic steatosis, liver inflammation, hepatitis C virus (HCV) infection and liver cancer (hepatocellular carcinoma).
Merck Sharp & Dohme LLC has identified compounds acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 (HCN1) and/or 2 (HCN2) blockers reported to be useful for the treatment of neuropathic pain, tinnitus, psychiatric and neurological disorders.
Gilead Sciences Inc. has synthesized indoline compounds acting as DNA helicase-primase complex (human herpes simplex virus) and viral replication inhibitors reported to be useful for the treatment of herpes virus infection.
Biogen Inc. has disclosed non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of stroke, psoriasis, arthritis, pain, silicosis, alopecia and more.
Kumquat Biosciences Inc. has described compounds acting as GTPase KRAS wild-type and mutant inhibitors reported to be useful for the treatment of cancer.